Outcome of patients with ELN22 adverse risk AML. (A) Outcome of patients with MR gene mutations (ie, mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2) compared with patients with TP53 mutations within the ELN22 adverse-risk group. (B) Outcome of patients with ASXL1 and/or RUNX1 mutations and patients with MR gene mutations other than ASXL1 and/or RUNX1 within the ELN22 adverse-risk category. (C) Outcome of patients with MR gene mutations, stratified by MR gene mutation VAF. (D) Outcome of patients with evidence of mutations in EZH2, STAG2, U2AF1, and ZRSR2. w/o, without.